Drug Page

A “not otherwise specified” (NOS) diagnosis is often used when an individual may have some symptoms related to a psychiatric diagnosis but does not meet enough criteria to warrant a particular diagnosis. A new study, published online ahead of print in Psychiatric Services, reveals that the proportion of mental health visits resulting in such NOS diagnoses rose to nearly fifty percent, and that these diagnoses do not result in more conservative psychiatric drug prescriptions.

More than ten-percent of adults in the United States are currently prescribed at least one psychiatric medication but there is currently a lack of research on the prevalence of adverse drug events (ADEs) associated with these prescriptions outside of clinical trials.

In an open letter to all US presidential candidates published Thursday in the BMJ, a group of global health care experts assert that current research regulations allow drug companies to publish incomplete and misleading results. They ask the candidates to declare whether they support improved transparency measures that would make data on drug studies publically available and open to scrutiny.

Infants exposed to SSRIs and benzodiazepines during pregnancy show impaired neurologic functioning in the first month after birth, according to a new study published in the American Journal of Psychiatry. While infants exposed SSRIs alone showed neurobehavioral effects throughout the first month, those exposed to an SSRI and a benzodiazepine had more significant problems.

In the third major verdict of its kind, drug giant Johnson & Johnson was ordered to pay a Maryland man who grew female breasts while taking the antipsychotic Risperdal. The company failed to warn doctors, patients, and regulators of the risk of abnormal breast development in young males and now faces about 5,400 lawsuits involving the drug.

The Washington Examiner reports that the manufacturer of the antipsychotic Abilify is seeking FDA approval for new digitized pills that would alert doctors if patients fail to take their drugs on schedule.

From 1999 to 2012 the percentage of Americans on antidepressants increased from 6.8% to 13%, according to a report published this week by the...

New York Times columnist, Nicholas Kristof, relates the story of Andrew Francesco, a boy who began taking Ritalin at age five and died from complications with Seroquel when he was fifteen. His father, a former pharmaceutical industry executive, reveals the industry’s greed in his memoir “Overmedicated and Undertreated.” Now the industry is pushing for a first-amendment right to market its drugs for off-label uses.

In 2014, then National Institute of Mental Health (NIMH) director, Thomas Insel, speculated that ketamine “might be the most important breakthrough in antidepressant treatment in decades.” A recent review of the research suggests that while ketamine may produce a rapid short-term improvement in depression, the effect is short-lived and the potential for addiction and dependence warrants considerable caution.

The UK Independent reports that Ireland is moving toward a policy of decriminalizing small amount of drugs like heroin, cocaine, and cannabis in what amounts to a “radical cultural shift.” While it would remain a crime to profit from the sale of these substances, users will have specially designated areas for safe use. The chief of Ireland’s National Drugs Strategy told the paper: “I am firmly of the view that there needs to be a cultural shift in how we regard substance misuse if we are to break this cycle and make a serious attempt to tackle drug and alcohol addiction.”

Giving money to people diagnosed with severe mental health issues can significantly improve depression and anxiety. A new study, published in the October issue of the Journal of Community Mental Health, found that giving about $73 US dollars per month for recreational spending can also reduce social isolation and strengthen a sense of self.

The percentage of seniors in the United States prescribed potentially deadly antipsychotic drugs increases with age. A new study reveals that in the face of serious risks of strokes, fractures, kidney injuries, and death, over seventy-five percent of seniors given antipsychotics do not have a diagnosis for a mental disorder.

Despite safety concerns, a new study reveals that there has been no change in the use of benzodiazepines in the elderly from 2001 to 2010.

In a bellwether case, plaintiffs allege that Pfizer did not adequately warn patients that Zoloft (sertraline) would cause birth defects. The case is scheduled in Federal Court in March, and the verdict will have significant implications for future suits.

The UK Times reports that pharmaceutical companies are actively lobbying to limit the release of clinical trial data to the public. Rather than limiting results and data to medical journals, new transparency initiatives are pushing for making the information publically available. The push for transparency comes in the wake of the reanalysis of the Study 329 data on paroxetine (marketed as Seroxat and Paxil), which found that the industry study had misconstrued its results.

Results of a new study reveal that sixty-nine percent, or more than two-thirds, of patients prescribed antidepressant drugs have never, in their medical history, met the criteria for major depression. The study, published in the Journal of Clinical Psychiatry this month, also found that several demographic factors, like race and gender, were associated with the prescription of antidepressants.

Last Tuesday, The New York Times and several other outlets (including Mad In America) reported on the highly-touted results of a study on psychosocial treatment for patients diagnosed with schizophrenia. Now, claims made about the study, which the ‘Times called “the most rigorous trial to date,” are coming under increased scrutiny.

This week the drug monitoring and patients' rights website, RxISK, launched the Centre for Medication Withdrawal, a page dedicated to establishing what causes dependence and how to treat it.

Writing on his 1 Boring Old Man blog, Dr. Mickey Nardo reflects on the media frenzy around the RAISE study and asks why the prescription data has not been released. He adds skepticism about the political motives of the potentially overblown results, which he sees as a clear push for increased mental health funding.

A massive number of meta-analyses of antidepressant clinical trials have financial conflicts of interest and are unduly influenced by pharmaceutical companies, according to a review to be published in an upcoming issue of the Journal of Clinical Epidemiology. Researchers also found that meta-analyses with industry ties almost never report any negative findings in their abstracts.

ITV features and article and video today about the widespread problem of addiction and withdrawal from benzodiazepine drugs used to treat anxiety, including Ativan, Librium, Diazepam and Temazepam. Mother of three Sandra Minshull shares her story and discusses how Ativan “robbed her of her life.”

A California jury ruled that Johnson & Johnson’s Janssen Pharmaceutical and a psychiatrist were responsible for the death of 25-year-old Leo Liu. During a clinical trial for Risperdal, Liu died of a heart injury that was “further complicated” by the drug and ignored by the study doctors. Janssen was found 70% responsible for Liu’s death and ordered to pay $5.6 million to the family.

The Scientific American reports on a new analysis of antidepressant trials revealing that the vast majority of meta-analyses have industry links and suppress negative results.

Yesterday, the New York Times reported that schizophrenia patients in an experimental treatment program (RAISE) who experienced better outcomes had been on lower doses of antipsychotics than normal. However, the article published in the American Journal of Psychiatry on Tuesday did not divulge any data on the varying antipsychotic drug doses in the different study groups.

Results of a large government-funded study call into question current drug heavy approaches to treating people diagnosed with schizophrenia. The study, which the New York Times called “by far the most rigorous trial to date conducted in the United States,” found that patients who received smaller doses of antipsychotic drugs with individual talk therapy, family training, and support for employment and education had a greater reduction in symptoms as well as increases in quality of life, and participation in work and school than those receiving the current standard of care.